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Biomarkers in NSCLC Epidermal Growth Factor Receptor
Mutations
Suzane Freidman
Abstract
Lung Cancer is the most common global cause of cancer related deaths in men and women (Markus, Alain, 2013). As
standard radiation and chemotherapy have proved ineffective, novel target therapies are in the midst of development. This review will analyze the success of the inhibitor drugs targeting the Epidermal Growth Factor Receptor (EGFR)
mutation, commonly found amongst Lung Cancer patients. Numerous studies and reviews are utilized to determine the
cause of the 10% success rate currently exhibited for these drugs. The L858R and E746-A750 point mutations and deletions respectively, were found prevalent in responsive patients as well as clinical-pathological features such as female
gender, Asian descent, non-smoking history, and Adenocarcinoma. Adenocarcinoma was found almost exclusively in
responsive patients and non-smoking history is proposed to have an independent correlation to EGFR mutations
(Kosaka, et.al. 2004). These prevailing features can be used as biomarkers to predict the responsiveness of a patient
population, leading to efficient and successful distrigution of the EGFR inhibition drug to Lung Cancer patients.
this protein is crucial to the development of biomarkers to
target specific populations containing the mutation to alThe Epidermal Growth Factor Receptor (EGFR), also known
low for further development of target therapy for cancer.
as ErbB1 or Her1 in humans, was first discovered by Stanley Cohen in the 1970’s (Yarden, Sliwkowski, 2001). Since Methods
then, our understanding of the protein and its critical role Various databases were utilized to gather papers on rein numerous forms of cancer has advanced in enormous search studies and reviews on the subject matter to anastrides. Advances in this area have proven to be fruitful, lyze it and determine possible biomarker methods and
and much hope is put into future development for cancer their efficiency. Articles were found in Google Scholar,
cures. EGFR is now understood to be one of four members Touro Library Database, and Rutgers University Dataof the ErbB interactive family of Tyrosine Kinase (TK) Pro- base. These papers were analyzed and used to come to
teins. EGFR, as well as ErbB 2, 3, and 4 (Her 2, 3, 4) are the conclusions explained in the discussion of this paper.
phosphorylation inducing proteins on the Tyrosine portion
of the receptors (Yarden, Sliwkowski, 2001). EGFR carries Results:
out numerous signal transduction pathways which result in EGFR
cellular proliferation, metastasis, and apoptotic aversion,
EGFR is a tri-domain membranous receptor protein conall clearly oncogenic activities. Consequently, EGFR comsisting of an extracellular ligand-binding domain mainly
monly causes numerous types of cancers whenevercomprised of cysteine, a hydrophobic transmembranous
expressed in epithelial tissue throughout the body (Heist,
area, and an intracellular Tyrosine Kinase Domain (Yarden,
Christiani, 2009). In Non Small Cell Lung Cancer (NSCLC)
2001). The Tyrosine Kinase domain is made up of a juxspecifically, EGFR over expression is the most common
tamembrane region, an area for TK activity, and a C cause, leading to much research and analysis of this proterminal domain (Markus, Alain, 2013). A number of ligtein, and its mutations in regard to lung cancer. Numerous
ands contain an affinity to EGFR including the Transforming
drug therapies have been developed to target the specific
Growth Factor-α (TGF-α), Epidermal Growth Factor (EGF)
mutations
that
were
found
as
causes
of
and Amphiregulin (Figure 1) (Huang, Harari,1999). All
NSCLC. Understanding of the structure and mechanism of
EGFR ligands contain around 50 amino acids including six
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cysteine residues in β-sheet formation and are highly regulated by numerous signal transduction pathways throughout the cell (Yarden, Sliwkowski, 2001). TGF-α is the most
common ligand (Vealel, et. al. 1987). Following EGFR binding, dimerization of EGFR occurs to form a homodimer
with an identical receptor or to form a heterodimer with a
different protein of the ErbB family (Isobe et. al.
2005). Heterodimers are stronger than homodimers with
a smaller rate of ligand dissociation, increased period of tie
at the cell surface, and increased mitogenic capabilities. Dimerization leads to autophosphorylation of Tyrosine residues of the cytoplasmic region of the protein itself. The specific regions activated on the Kinase domain,
and consequently the specific pathways activated, are dependent on the ligand’s identity as well as EGFR’s dimerization partner. EGFR’s activation allows it to bind to cytoplasmic messenger proteins which initiate various signal
transduction cascades resulting in cell proliferation, metastasis, and apoptosis aversion (Yarden, Sliwkowski, 2001).

sidered linear, in reality it involves many complex interactions with other pathways which regulate the different
steps, mainly Raf Activation. Studies have shown that mutations in each step along the path of this complex pathway are present in a substantial percentage of cancers and
other disorders. This complexity can be demonstrated
with an example involving EGFR. EGFR is involved in the
upstream and downstream regulation of the MAPK pathway. EGFR functions upstream by signaling the Ras protein
in which case an EGFR mutation or over expression can
cause hyperactivation of the MAPK pathway. Additionally,
one of the products of ERK signaling is TGF-α and other
EGFR ligands whose over expression can lead to hyperactivation of the pathway as well. In order to combat the numerous mutations which present themselves throughout
this pathway, intense study and research is currently devoted to the development of Raf inhibitors, MEK inhibitors,
Ras inhibitors, and EGFR inhibitors- our area of interest
(Roberts, Der, 2007).

Raf-MEK-ERK Mitogen-Activated Protein Kinase
Cascade

EGFR Inhibitors
As a result of the large proportion of EGFR mutations among Non Small Cell Lung Cancer, much effort has
been devoted to the research and development of inhibitor drugs which combat the neoplasia resulting from the
over-expression of the EGFR proteins. Novel target therapies in the midst of development can aim at the specific
EGFR oncogene as opposed to affecting all the cells in the
body with chemotherapy, which has proven itself relatively
ineffective in treatment of lung cancer (Vealel, et. al.
1987). Various research groups are exploring distinct
methods of inhibiting the hyperactivity of the EGFR pathway. This inhibition is relatively harmless because the
EGFR pathway does not play an essential role in the bodies
of healthy adults, its inhibition causing a rash or diarrhea at
most (Fukuoka, et. al. 2003). Aside for the EGFR signal
transduction pathway inhibitors discussed earlier, there
are two forms of inhibitors of the EGF receptor itself currently in the form of marketable drugs. These two forms
of inhibitors are monoclonal antibodies and tyrosine kinase
inhibitors. Researchers are currently attempting to find
the optimal combination of these two target therapies together with standard radiation and chemotherapy for each
case of Lung Cancer. Monoclonal antibodies, such as Ce-

The most common EGFR signal transduction pathway is the Raf-MEK-ERK Mitogen-Activated Protein Kinase
Cascade (Figure 2). This cascade contains a set of its own
mutations throughout the steps of the pathway which are
leading causes of cancer as well. Mammalian cascades
involving Mitogen-Activated Protein Kinases (MAPK’s) are
part of a three step signaling process. The MAPK Kinase
Kinase (MAPKKK) signals the MAP Kinase (MAPKK) which
then signals the MAPK (Roberts, Der, 2007). In the EGFR
MAPK cascade, active EGFR stimulates Raf, the MAPKKK,
through association with adaptor protein Grb2 which recruits SOS-1 nucleotide exchange factors to the cell membrane. SOS-1 activates Ras proteins by exchanging the
GDP bound to Ras for GTP. The activated Ras recruits Raf
to the cell membrane and activates it through a complex
process involving phosphorylation (Friday, Adjei,
2008). The Raf MAPKKK phosphorylates and activates MEK
1 and 2, the MAPKK’s, which phosphorylate the MAPK’sExtracellular signal-regulated kinases (ERK 1 and
2). Activated ERK’s go on to regulate numerous proteins
and transcription factors, resulting in cell proliferation and
survival. Although this pathway has previously been con80
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tuximab, are large molecules that act from outside of the
cell. These antibodies inhibit EGFR activation by binding
close enough to the ligand-binding site that it can block the
ligand from binding to the receptor (Friday, Adjei, 2008).

international phase III Erlotinib trial was randomized, double blind, and placebo controlled with a 2:1 ratio of 150mg
daily dose of Erlotinib to the placebo group. The placebo
was considered ethical because further chemotherapy
would not have benefitted these patients whose first or
second bout of chemotherapy had failed. Response rate
was around 9% in the group who received Erlotinib and
less than 1% in the placebo group. Median survival was
prolonged by two months (Shepherd, et. al. 2005).

Our inhibition drugs of interest are Tyrosine Kinase
Inhibitors. Tyrosine kinase inhibitors are small molecules
with the ability to move through the cell membrane in order to interact with the cytoplasmic EGFR domain. Tyrosine kinase inhibitors exhibit competitive inhibition, binding to the tyrosine residues of the EGF receptor,
thereby blocking ATP from binding and activating the EGFR
and its downstream effectors. This inhibition of the EGFR
pathway has demonstrated clinical response and has prolonged life expectancy of EGFR mutation patients. It is believed that the tyrosine kinase inhibitors discontinue the
translation of EGFR effectors which had induced cellular
proliferation and metastasis, thereby reducing the excessive cell growth present in the malignancy (Massutí,
2003). Furthermore, it was proposed that tyrosine kinase
inhibition induces apoptotic cell death by upregulation of
Bim, a pro-apoptotic protein. Another strong possibility is
that tyrosine kinase inhibitors induce cell death by inhibiting mTOR, an autophagy-inhibitor protein whose activity
is normally increased by EGFR activity. Autophagy is the
process of which the cellular organelles are swallowed up
by lysosomal vesicles, but this process is normally regulated by the EGFR pathway. With the EGFR pathways halted,
this inhibition is weakened and autophagy becomes more
prevalent amongst the malignant cells causing the desired
cell death (Markus, Alain, 2013).

EGFR Mutations
The control that EGFR contains over cell proliferation and metastasis makes it a key protein for oncogenic
mutation. Hyperactivity of the EGFR pathway in any step
of its complex network can lead to neoplasia. This can
happen through mutation, over expression, or amplification of EGFR, its ligands, or a protein involved in the EGFR
pathway.
In a study done in Japan (Kosaka, et. al. 2004), tumor samples were obtained from 277 randomly selected patients
(Figure 3). Exons 18-21, the first four exons that code for
the Tyrosine Kinase domain, were amplified and underwent molecular analysis, as these areas had been previously shown to contain the EGFR mutations in conducted studies. Mutations in this area of the tumor’s EGFR gene were
found in 111 patients (40%). There were 52 in-frame deletion mutations, 54 point mutations, and 5 duplication/
insertion mutations. The deletions were all around the five
amino acids ELREA from codons 746-750 of exon
19. Approximately half were simple deletions and half
were deletions coupled with point mutations or insertions. A Thymine to Guanine exchange at the second nucleotide of codon 858 in exon 21 was found in 85% of the
point mutations, leading to an exchange of Leucine for Arginine. In summary, 91% of the EGFR mutations occurred
as deletions around E746-A750 or as L858R point mutations. These two forms of mutations have come up in numerous studies conducted in this area, proving to be
strongly correlated with EGFR mutational Non-Small Cell
Lung Cancer (NSCLC).

Two TKI drugs currently on the market are Gefitinib/Iressa and Erlotinib/Tarceva. In the randomized,
double blind, Phase II trial of Gefitinib, the results were
promising. Included in the study were 210 advanced
NSCLC patients who had been treated with chemotherapy
once or twice and had received platinum treatment. They
were chosen to receive a daily oral dose of either 250-mg
or 500-mg Gefitinib. Tumor response rates were approximately 19% and the symptom improvement rate of evaluable patients was approximately 40%. Adverse effects were
minimal in both cases consisting main of diarrhea and skin Clinical Features Correlated to EGFR Aberration
rashes (Fukuoka, et. al. 2003).
As numerous studies were conducted, specific
The Erlotinib results seem optimistic as well. The patterns of clinical and pathological features were found to
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be present in the lung cancer patients involved in the studies. Female gender, non-smoking history, Asian descent,
and Adenocarcinoma were all found to be directly related
to EGFR mutations in NSCLC. EGFR mutations are almost
completely exclusive to adenocarcinomas in all conducted
studies. In the Japanese study, only one out of 111 EGFR
mutated patients had nonadenocarcinoma. In a similar
study conducted in Italy (Marchetti, et. al.2005), EGFR mutations were found exclusively in the adenocarcinoma patients. Smoking history showed significantly high statistical
correlation to EGFR mutations as well. Fifty nine percent
of the patients in the Italian study with mutated EGFR proteins were nonsmokers and 41% were smokers or former
smokers. The study in Japan takes this smoking correlation
a step further after completing more advanced statistical
analysis solely on the Adenocarcinoma patients. They divided the smokers into three categories depending on the
length of the period of time spent smoking, and it was discovered that the higher the exposure to smoking, the lower the percentage of EGFR mutation was found in that subgroup of patients, refuting the hypothesis that smoking is
related to NSCLC.

ous times for having a higher proportion of EGFR mutation
than American NSCLC patients (Kosaka, et. al.
2004). However, this feature is likely a result of other commonly found features in Asian populations. There are a
significantly lower percentage of NSCLC patients with a
history of smoking in Japan than in America. In the Japanese study, 83% of the female and 10% of the male patients were non-smokers, which is typical of Japanese patients. The conductors of this study note that in a parallel
American study, however, 15% of the female and 6% of
the male patients were never-smokers. These results were
characteristic of many studies which evaluated American
versus Asian smoking history.

Discussion
There has been great success in the area of EGFR target
therapy, as well as with target therapy in general as a cure
for cancer. However, in order to continue in the path toward success, clearer biomarkers must be established
which can help to narrow down the population to which
the drug is originally administered. Currently, the percentage of response to EGFR TKI’s is only around 10%
(Fukuoka, et. al. 2003, Shepherd,et. al. 2005). The current
goal of the ongoing research in this area is to hone in on
this 10% of patients, using research and experimentation
to solve the mystery of their success. Eventually, as the
response to each target therapy is clearly understood,
each patient will be given his or her optimal drug combination, and greater response rates will be seen with cancer
patients worldwide.

In terms of gender, in both the Japanese and Italian studies as well as numerous other studies conducted
on this subject, the females were a significantly larger percentage of the NSCLC patients found with the EGFR mutation. However, because female patients are usually nonsmokers as well as Adenocarcinoma type cancer patients,
the Japanese study performed logistic regression analysis
to determine if gender contributed independently to EGFR
mutation. The result demonstrated that only Adenocarcinoma histology and smoking status contributed independently to EGFR mutation, while female gender was an
outcome of the other features that were present amongst
females in a higher percentage than males. Similar results
were found in many other studies as well. Furthermore,
an added observation was made on the small number of
patients under the age of 50, menopause age in Japan. It
was found that the EGFR mutation in these younger patients did not lean toward the female gender, further discounting theories of hormonal activity affecting the EGFR
protein in females.

An integral step toward this goal is the determination of objective patient features for each target therapy
which will signal success (or failure) in the inhibition of the
gene of interest. A standard, quantitative scoring system
for assessment must be established to determine if the
target therapy is, in actuality, blocking what it was intended to block and if that blockage elicits a positive clinical
response. New technology is being developed to assist the
research in this area such as cDNA Arrays which will allow
the identification of genes regulated by anti-EGFR therapies. Protein Arrays could be used to explore the proteins
involved in the EGFR pathways (Baselga, Arteaga, 2005).
Once clear signs of drug success have been estab-

Japanese NSCLC patients were confirmed numer82
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lished, it is necessary to explore the correlation between
clinical-pathological patient biomarkers and drug success
(or failure). Research is being conducted to explore the
patterns of clinical patient features which are more prevalent among patients who responded to the drug. The two
forms of biomarkers being researched amongst NSCLC patients are genetics and clinical characteristics. The genetic
sequence mutations amongst EGFR NSCLC patients are
somewhat clear. The two main mutations are the E746A750 deletion as well as the L858R point mutation. However, the clinical patient features commonly prevalent in
EGFR mutation patients must be examined further. In order to accomplish this goal, there are those who believe
that a “No tissue-No trial” rule should be enacted in which
a patient whose molecules of interest are unclear in the
tissue would be excluded from the trial. This way, only
patients who will help research further its goal of establishing a connection between drug response and biomarkers
would be granted the drug (Baselga, Arteaga, 2005).

However, the connection between EGFR mutation
and the independent characteristics of adenocarcinoma
and smoking history are pretty firmly established. Fukuoka
(2003) postulates that the slow growth of adenocarcinomas may lend itself to successful drug response.

Conclusion
The true link between prevalent clinical traits and
drug response rate can only be understood with a deeper
understanding of the complex EGFR network of signal
transduction pathways and cross talk found amongst them.
This will be possible with the use of technology such as
genetic and protein arrays as well as analysis of future
studies. This understanding, coupled with the knowledge
of clear biomarkers, will allow for target drug administration to specific populations and higher response rates in
EGFR inhibitor drugs. Target cancer drugs will eventually
be administered to the small percentage of the population
who will likely respond to the drug, thereby efficiently creating a higher success rate of target therapy.

In terms of clinical features, it seems that the two
characteristics which independently correlate to EGFR mutation are adenocarcinoma type cancer and non-smoking
history. Female gender prevalence in drug response is a
likely outcome of its correlation to Adenocarcinoma and
non-smoking history. The results of the logistic regression
analysis in many studies and trials did not point to female
gender with an independent correlation to drug response. Additionally, the analysis of the pre-menopause
patients in the Japanese study points to the same conclusion; female gender does not independently correlate with
EGFR inhibition response rate. In the Gefitinib trial, no
pharmacokinetic differences were found between men and
women (Fukuoka, et. al. 2003).
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